Argos Therapeutics (ARGS) Stock Price Down 7.2%

Argos Therapeutics Inc (NASDAQ:ARGS)’s share price was down 7.2% on Monday . The stock traded as low as $1.34 and last traded at $1.28. Approximately 869,216 shares changed hands during mid-day trading, a decline of 0% from the average daily volume of 871,282 shares. The stock had previously closed at $1.38.

Separately, ValuEngine raised Argos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

The company has a market cap of $5.64, a PE ratio of -0.06 and a beta of 1.36. The company has a debt-to-equity ratio of -1.46, a quick ratio of 2.29 and a current ratio of 2.29.

A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. bought a new stake in Argos Therapeutics Inc (NASDAQ:ARGS) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned approximately 1.21% of Argos Therapeutics at the end of the most recent reporting period.

COPYRIGHT VIOLATION NOTICE: “Argos Therapeutics (ARGS) Stock Price Down 7.2%” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply